Related Experiment Video

Updated: Oct 4, 2025

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.3K

Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment

Nida Pasha1, Nicholas C Turner2,3

  • 1Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

Nature Cancer
|February 5, 2022
PubMed

Insights

Targeted therapies improve metastatic breast cancer outcomes, but treatment resistance persists. This review explores genomic drivers of tumor diversity and resistance mechanisms to inform future strategies.

Area of Science:

  • Oncology
  • Genomics
  • Cancer Biology

Background:

  • Targeted therapies have transformed metastatic breast cancer (MBC) treatment.
  • Treatment resistance remains a significant clinical challenge in MBC.
  • Tumor clonal diversity is increasingly recognized as a driver of resistance.

Purpose of the Study:

  • To review the genomic processes underlying tumor heterogeneity in MBC.
  • To elucidate mechanisms of resistance to MBC therapies.
  • To discuss future therapeutic strategies informed by resistance biology.

Main Methods:

  • Literature review focusing on genomic alterations and resistance mechanisms in MBC.
  • Analysis of studies linking tumor heterogeneity to treatment outcomes.
  • Synthesis of current knowledge on clonal evolution in metastatic breast cancer.

Main Results:

  • Genomic instability and specific mutations drive tumoral heterogeneity.
  • Clonal evolution allows for the outgrowth of resistant cell populations.
  • Diverse mechanisms contribute to resistance, including genetic and epigenetic alterations.

Conclusions:

  • Understanding genomic drivers of heterogeneity is crucial for overcoming MBC resistance.
  • Targeting resistance mechanisms and exploiting tumor diversity are key for future MBC therapies.
  • Personalized treatment strategies accounting for clonal evolution are needed.

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.2K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.8K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K